Canopy Growth Corporation (CGC) Dividend Safety Gauge & 10-Year DRIP Compounder

CGC scores 41 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 11 / 20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 6 / 20 (institutional accumulation and options positioning), Insider Conviction at 7 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 7 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

Taken together, the pillar scores point to weakness across cash generation, institutional and insider support, and balance-sheet strength. The Piotroski F-Score of 1 out of 9 is a low reading on the forensic checklist. The Altman Z-Score of 2.5 is reported alongside it, and the Debt/Equity of 0.5 provides some context on leverage. For a prospective investor, the upside case would need to rest on a turnaround in cash generation or a shift in flow data, neither of which is demonstrated in the supplied figures. The verdict and pillar breakdown are educational indicators of the rating framework, not personalized financial advice.

Canopy Growth Corporation is listed on NASDAQ under the ticker CGC.. Customer base, product lines, and revenue model are — The profile reports a market capitalization of $0.3B.

Reported net income was -$526.0M for FY 2023, -$354.0M for FY 2024, and -$189.0M for FY 2025, with revenue and operating income each shown as — across all three periods. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is 0%. The Forensic Balance Sheet pillar cites an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and Debt/Equity of 0.5 . Cash and debt balances are N/A in the financial periods provided.

• 🐂 Primary Bull Case: Shareholders have authorized a reverse split of up to 1-for-15, a step that could address the sub-$1 listing compliance issue flagged in the news flow. With Fundamental Cash Engine at 11/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $0.64 – $2.38 52-week range.
• 🐻 Primary Bear Case: The RQD rating of 41 (D-) is driven by 0% ROIC, 0% FCF yield, and a Piotroski F-Score of 1 out of 9, with net losses reported in each of the three fiscal years provided. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations beyond the stated Health Care classification, and 2nd-order bottlenecks are —

• Key Question #1: How does the 1-for-15 reverse split authorization interact with the Nasdaq compliance deadline, and what is the timing of any implementation?
• Key Question #2: What are cash and debt balances, and how do they reconcile with the reported Debt/Equity of 0.5 and Altman Z-Score of 2.5?
• Key Question #3: How sensitive is CGC's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?